Skip to main content
. 2018 Jan 19;9(11):9808–9824. doi: 10.18632/oncotarget.24275

Figure 4. RRD-251 enhances D3-induced CD14 expression.

Figure 4

HL-60 cells were untreated (C) or treated with 0.5 μM D3, 10 μM RRD-251, or D3 plus 10 μM RRD-251 for each designated time point. Statistically significant changes are labeled b and d on the graphs and significant changes between D3 and RRD-251 plus D3 are highlighted. (A) CD14 expression (assessed by flow cytometry with a PE-conjugated antibody) at 24 hours post treatment is increased by D3 and enhanced by RRD-251 co-treatment (C vs. D3 p=0.0017; C vs. RRD-251 + D3 p<0.0001; D3 vs. RRD-251 + D3 p<0.0001). (B) At 48 hours post treatment RRD-251 continues to augment D3-induced CD14 expression (D3 vs. RRD-251 + D3 p=0.0099). (C) D3-induced CD14 expression remains increased with addition of RRD-251 at 72 hours post treatment (D3 vs. RRD-251 + D3 p=0.0024).